Articles

Caplacizumab, a game changer in the treatment of acquired thrombotic thrombocytopenic purpura

BJH - volume 11, issue 3, may 2020

N. De Beule MD, PhD, R. Schots MD, PhD, A. De Becker MD

SUMMARY

Acquired or immune-mediated thrombotic thrombocytopenic purpura (aTTP) is a life-threatening auto-immune disorder caused by a functional deficiency of the von Willebrand factor-cleaving protease ADAMTS13, leading to thrombotic microangiopathy. The introduction of plasma-exchange has reduced mortality from over 90% to 10–20%. However, over the last two decades the treatment outcomes have not changed substantially. Caplacizumab, a humanised nanobody directed to the A1 domain of VWF, inhibits this lethal thrombotic cascade and is therefore essential for symptom control and prevention of irreversible end-organ damage. Both TITAN and HERCULES trials demonstrated that treatment with caplacizumab significantly reduced mean duration of hospitalisation and number of days of plasma-exchange. Moreover, no deaths were observed in caplacizumab-treated patients. Therefore, we can state that caplacizumab has changed the treatment paradigm of aTTP.

(BELG J HEMATOL 2020;11(3):120–7)

Read more

O.2 AXL: A potential therapeutic target to eliminate cancer cells and improve chemotherapeutic responses in different hematological cancers

BJH - volume 11, issue Abstract Book BHS, february 2020

N. Vandewalle , P. Vlummens MD, N. De Beule MD, PhD, S. Faict , I. Oudaert , dr. K. Maes , E. De Bruyne , E. Menu , K. Vanderkerken PhD, K. De Veirman

Read more

P1.04 Tumor-associated macrophages induce Multiple Myeloma cell survival and STAT3 activation

BJH - volume 7, issue Abstract Book BHS, january 2016

N. De Beule MD, PhD, K. De Veirman , dr. K. Maes , E. De Bruyne , E. Menu , R. Schots MD, PhD, K. Vanderkerken PhD, E. Van Valckenborgh PhD

Read more

P1.01 Myeloid Derived Suppressor Cells induce Multiple Myeloma cell survival through AMPK activation

BJH - volume 6, issue Abstract Book BHS, january 2015

K. De Veirman , J. van Ginderachter , N. De Beule MD, PhD, S. Lub , A. Maes , E. De Bruyne , E. Menu , I. Van Riet PhD, K. Vanderkerken PhD, E. Van Valckenborgh PhD

Read more

P.34 Multiple Myeloma in the era of novel agents: a single center experience

BJH - 2013, issue BHS Abstractbook, january 2013

N. De Beule MD, PhD, K. Fostier MD, A. De Becker MD, C. Caron , F. Trullemans , R. Schots MD, PhD

Read more
X